358 related articles for article (PubMed ID: 32296648)
1. Verotoxin Receptor-Based Pathology and Therapies.
Lingwood C
Front Cell Infect Microbiol; 2020; 10():123. PubMed ID: 32296648
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Uses of Bacterial Subunit Toxins.
Lingwood C
Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34073185
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs.
Boyd B; Tyrrell G; Maloney M; Gyles C; Brunton J; Lingwood C
J Exp Med; 1993 Jun; 177(6):1745-53. PubMed ID: 8496689
[TBL] [Abstract][Full Text] [Related]
4. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues.
Kiarash A; Boyd B; Lingwood CA
J Biol Chem; 1994 Apr; 269(15):11138-46. PubMed ID: 8157640
[TBL] [Abstract][Full Text] [Related]
5. [Verotoxin induced hemolytic uremic syndrome: pathophysiology of neurological involvement].
Takagi C; Naruse T
Nihon Rinsho; 1997 Mar; 55(3):731-5. PubMed ID: 9086789
[TBL] [Abstract][Full Text] [Related]
6. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology.
Khan F; Proulx F; Lingwood CA
Kidney Int; 2009 Jun; 75(11):1209-1216. PubMed ID: 19212418
[TBL] [Abstract][Full Text] [Related]
7. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells.
Legros N; Dusny S; Humpf HU; Pohlentz G; Karch H; Müthing J
Glycobiology; 2017 Jan; 27(1):99-109. PubMed ID: 27558838
[TBL] [Abstract][Full Text] [Related]
8. Blood group P1 antigen-bearing glycoproteins are functional but less efficient receptors of Shiga toxin than conventional glycolipid-based receptors.
Morimoto K; Suzuki N; Tanida I; Kakuta S; Furuta Y; Uchiyama Y; Hanada K; Suzuki Y; Yamaji T
J Biol Chem; 2020 Jul; 295(28):9490-9501. PubMed ID: 32409578
[TBL] [Abstract][Full Text] [Related]
9. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells.
Legros N; Pohlentz G; Steil D; Müthing J
Int J Med Microbiol; 2018 Dec; 308(8):1073-1084. PubMed ID: 30224239
[TBL] [Abstract][Full Text] [Related]
10. Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry.
Szymczak-Kulus K; Weidler S; Bereznicka A; Mikolajczyk K; Kaczmarek R; Bednarz B; Zhang T; Urbaniak A; Olczak M; Park EY; Majorczyk E; Kapczynska K; Lukasiewicz J; Wuhrer M; Unverzagt C; Czerwinski M
J Biol Chem; 2021; 296():100299. PubMed ID: 33460651
[TBL] [Abstract][Full Text] [Related]
11. Generation of receptor-active, globotriaosyl ceramide/cholesterol lipid 'rafts' in vitro : A new assay to define factors affecting glycosphingolipid receptor activity.
Nutikka A; Lingwood C
Glycoconj J; 2004; 20(1):33-8. PubMed ID: 14973368
[TBL] [Abstract][Full Text] [Related]
12. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms.
Van Setten PA; van Hinsbergh VW; Van den Heuvel LP; van der Velden TJ; van de Kar NC; Krebbers RJ; Karmali MA; Monnens LA
J Am Soc Nephrol; 1997 Dec; 8(12):1877-88. PubMed ID: 9402090
[TBL] [Abstract][Full Text] [Related]
13. AB5 Preassembly Is Not Required for Shiga Toxin Activity.
Pellino CA; Karve SS; Pradhan S; Weiss AA
J Bacteriol; 2016 Jun; 198(11):1621-1630. PubMed ID: 27002129
[TBL] [Abstract][Full Text] [Related]
14. Escherichia coli Shiga toxin.
Nakao H; Takeda T
J Nat Toxins; 2000 Aug; 9(3):299-313. PubMed ID: 10994531
[TBL] [Abstract][Full Text] [Related]
15. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
[TBL] [Abstract][Full Text] [Related]
16. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)--associated hemolytic-uremic syndrome.
Karch H
Semin Thromb Hemost; 2001 Jun; 27(3):207-13. PubMed ID: 11446654
[TBL] [Abstract][Full Text] [Related]
17. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis.
Johansson D; Kosovac E; Moharer J; Ljuslinder I; Brännström T; Johansson A; Behnam-Motlagh P
BMC Cancer; 2009 Feb; 9():67. PubMed ID: 19245689
[TBL] [Abstract][Full Text] [Related]
18. Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor.
Johansson K; Willysson A; Kristoffersson AC; Tontanahal A; Gillet D; Ståhl AL; Karpman D
Front Cell Infect Microbiol; 2020; 10():212. PubMed ID: 32523894
[TBL] [Abstract][Full Text] [Related]
19. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
Arbus GS
Kidney Int Suppl; 1997 Mar; 58():S91-6. PubMed ID: 9067954
[TBL] [Abstract][Full Text] [Related]
20. Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals.
Mainil J
Vet Res; 1999; 30(2-3):235-57. PubMed ID: 10367357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
